| Literature DB >> 29966464 |
Samuel Romero1,2, Juan Montoro1,2, Marta Guinot1,2, Luis Almenar3, Rafael Andreu1,2, Aitana Balaguer1,2, Isabel Beneyto4, Jordi Espí4, José Gómez-Codina5, Gloria Iacoboni1,2, Isidro Jarque1,2, Rafael López-Andújar6, Empar Mayordomo-Aranda7, Joaquín Montalar5, Amparo Pastor8, Miguel Pastor5, José L Piñana1,2, Nohelia Rojas-Ferrer7, Ignacio Sánchez-Lázaro3, Jesús Sandoval9, Guillermo Sanz1,2,10, Miguel Á Sanz1,2,10, Amparo Solé8, Jaime Sanz1,2.
Abstract
Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p < .0001). PTLD was EBV-positive in 100% of allo-HSCT, in contrast to 47% of SOT (p = .0002). Four years after PTLD diagnosis, median overall survival was 32% (95% CI, 22-48) and 10% (95% CI, 2-49) in SOT and allo-HSCT recipients, respectively (p = .002). In conclusion, the clinical presentation and the outcome of PTLD varies greatly depending on the type of transplant.Entities:
Keywords: Epstein–Barr virus; Solid organ transplantation; hematopoietic stem cell transplantation; immunosuppression; post-transplant lymphoproliferative disorders
Mesh：
Year: 2018 PMID： 29966464 DOI： 10.1080/10428194.2018.1474462
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022